Investor
COVID-19 has changed the healthcare workforce, but automation could be the future.
The company said its valuation is now $1.4 billion.
The latest round follows a $14 million Series B raise from 2019.
The company said the Series B brings its total raise to $20 million.
The company plans to put the new funds towards building out its platform.
The company said it’s app analyzes weekly urine tests to provide nutrition and lifestyle guidance.
The company, formerly named Thryve, also hired a new CEO and a chief product officer.
This new infusion of cash brings the company's total funding to $28 million.
The new technology is being developed for in-hospital and at-home use.
The funding will help clinicians manage elective recovery backlogs in the NHS.